Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)

Safety, tolerability and pharmacokinetics of single dose of BI 655066/ABBV-066 (risankizumab) in healthy Chinese, Japanese and Caucasian male volunteers.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: ABBV-066; Drug: ABBV-066; Drug: Placebo; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 80
• Phase: Phase 1

Contacts and Locations

Study Locations

• Japan
  • Tokyo, Sumida-ku, Japan
    • Boehringer Ingelheim Investigational Site
• Korea, Republic of
  • Busan, Korea, Republic of
    • Boehringer Ingelheim Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion criteria:

1. Healthy male subjects according to the investigator¿s assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests

2. Chinese ethnicity, Japanese ethnicity, or Caucasian according to the following criteria:

   • Chinese; born in China or ethnic Chinese born outside of China, and a descendent of 4 ethnic Chinese grandparents who were all born in china
   • Japanese; born in Japan, have lived outside of Japan <10 years, and have parents and grandparents who were all born in Japan
   • Caucasian
3. Age of 20 to 45 years (incl.)
4. BMI of 18.5 to 25 kg/m2 (incl.) for Chinese and Japanese subjects, BMI of 18.5 to 29.9 kg/m2 (incl.) for Caucasian subjects.
5. Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation.

6. Male subjects who agree to minimize the risk of female partners becoming pregnant by fulfilling any of the following criteria starting from at least 30 days before the first administration of trial medication and until 30 days after trial completion:

   • Use of adequate contraception, e.g. any of the following methods plus condom: implants, combined oral or vaginal contraceptives, intrauterine device
   • Sexually abstinent
   • Vasectomised (vasectomy at least 1 year prior to enrolment)
   • Surgically sterilised (including hysterectomy)

Exclusion criteria:

1. Any finding in the medical examination (including BP, PR or ECG) is deviating from normal and judged as clinically relevant by the investigator
2. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
3. Any evidence of a concomitant disease judged as clinically relevant by the investigator
4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
5. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication (except appendectomy and simple hernia repair)
6. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
7. History of relevant orthostatic hypotension, fainting spells, or blackouts
8. Chronic or relevant acute infections including HIV, viral hepatitis and (or) tuberculosis or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold (or T-SPOT) test. Subjects with a positive QuantiFERON TB-Gold (or T-SPOT) test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines.
9. History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
10. Intake of biologic agents other than current study medication or drugs considered likely to interfere with the safe conduct of the study
11. Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10 half-lives of the respective drug prior to administration of trial medication
12. Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial or that might prolong the QT/QTc interval
13. Participation in another trial with an investigational drug within 90 days or 5 half-lives (whichever is greater) prior to planned administration of trial medication
14. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
15. Inability to refrain from smoking on specified trial days
16. Alcohol abuse (consumption of more than 30 g per day)
17. Drug abuse or positive drug screening
18. Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
19. Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
20. Inability to comply with dietary regimen of trial site
21. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
22. A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
23. Have received any live bacterial or live viral vaccination in the 12 weeks prior to the date of screening. Subjects must agree not to receive a live bacterial or live viral vaccination during the study and up to 12 months after the last administration of study drug
24. Have received Bacille Calmette-Guerin (BCG) vaccination in the 12 months prior to the date of screening. Subjects must agree not to receive BCG vaccination during the study and up to 12 months after the last administration of study drug
25. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Stage 1 (low dose SC); Low dose administered by subcutaneous (SC) injection	Drug: ABBV-066; SC injection; Other Names: BI 655066; risankizumab; Drug: ABBV-066; IV infusion; Other Names: BI 655066; risankizumab
Experimental: Stage 1 (medium dose SC); Medium dose administered by subcutaneous (SC) injection	Drug: ABBV-066; SC injection; Other Names: BI 655066; risankizumab; Drug: ABBV-066; IV infusion; Other Names: BI 655066; risankizumab
Experimental: Stage 1 (high dose SC); High dose administered by subcutaneous (SC) injection	Drug: ABBV-066; SC injection; Other Names: BI 655066; risankizumab; Drug: ABBV-066; IV infusion; Other Names: BI 655066; risankizumab
Experimental: Stage 2 (low dose IV); Low dose administered by intraveneous (IV) infusion	Drug: ABBV-066; SC injection; Other Names: BI 655066; risankizumab; Drug: ABBV-066; IV infusion; Other Names: BI 655066; risankizumab
Experimental: Stage 2 (medium dose IV); Medium dose administered by intraveneous (IV) infusion	Drug: ABBV-066; SC injection; Other Names: BI 655066; risankizumab; Drug: ABBV-066; IV infusion; Other Names: BI 655066; risankizumab
Experimental: Stage 2 (high dose IV); High dose administered by intraveneous (IV) infusion	Drug: ABBV-066; SC injection; Other Names: BI 655066; risankizumab; Drug: ABBV-066; IV infusion; Other Names: BI 655066; risankizumab
Placebo Comparator: Placebo SC (Stage1); Placebo administered by subcutaneous (SC) injection	Drug: Placebo; SC injection (stage 1); Drug: Placebo; IV infusion (stage 2)
Placebo Comparator: Placebo IV (Stage2); Placebo administered by intraveneous (IV) infusion	Drug: Placebo; SC injection (stage 1); Drug: Placebo; IV infusion (stage 2)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of subjects with drug-related adverse events	Up to 144 days after screening

Secondary Outcome Measures

Outcome Measure	Time Frame
Time from dosing to the maximum plasma concentration of the analyte in plasma (tmax)	Up to 144 days after randomization
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to time of the last quantifiable plasma concentration (AUC0-tz)	Up to 144 days after randomization
Maximum measured plasma concentration of the analyte in plasma (Cmax)	Up to 144 days after randomization
Terminal half-life of the analyte in plasma (t1/2)	Up to 144 days after randomization
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)	Up to 144 days after randomization

Collaborators and Investigators

• Sponsor: AbbVie
• Collaborators: Boehringer Ingelheim

Publications and helpful links

General Publications

• Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30.
• Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019 Oct;58(10):1309-1321. doi: 10.1007/s40262-019-00759-z.

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2015
• Primary Completion (Actual): June 1, 2017
• Study Completion (Actual): June 1, 2017

Study Registration Dates

• First Submitted: August 12, 2015
• First Submitted That Met QC Criteria: November 3, 2015
• First Posted (Estimate): November 4, 2015

Study Record Updates

• Last Update Posted (Actual): July 6, 2017
• Last Update Submitted That Met QC Criteria: July 5, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Keywords: ABBV-066; BI 655066; risankizumab
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Antibodies, Monoclonal
• Other Study ID Numbers: M16-513; 1311.16 (Other Identifier: Boehringer Ingelheim)